Saving cognitive outcome data in Alzheimer's disease clinical trials during the COVID‐19 pandemic: Commentary on the virtual administration of the ADAS‐Cog

Elderly participants in Alzheimer's disease (AD) clinical trials are at high risk of morbidity and mortality with interpersonal exposure to COVID‐19, a situation that is likely to continue for the foreseeable future. Yet, in‐person neuropsychological assessments remain the mainstay primary outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwab, Nadine A., DesRuisseaux, Libby A., Weinberg, Marc S., Arnold, Steven E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744007/
https://www.ncbi.nlm.nih.gov/pubmed/33344748
http://dx.doi.org/10.1002/trc2.12081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744007/
https://www.ncbi.nlm.nih.gov/pubmed/33344748
http://dx.doi.org/10.1002/trc2.12081

Ejemplares similares